Arcadia Biosciences Q3 revenue rises 24% to record high
RKDA•Arcadia Biosciences reported Q3 revenue of $1.62 million, up 24% year over year and a record for its Zola brand. Net income attributable to common stockholders more than doubled to $1.76 million.
1. Quarterly results
Q3 revenue rose 24% year over year to $1.62 million, the highest ever for the Zola brand. Net income attributable to common stockholders more than doubled to $1.76 million, while operating expenses were $2.46 million.
2. Drivers and plans
The company said strong summer-program volumes drove revenue growth. Net income improvement was mainly due to a $2.6 million gain related to the change in estimated fair value of common stock warrant and option liabilities; cost of revenues also fell due to a tariff refund of about $175,000 in July 2026. Arcadia plans to begin shipping a new 1L espresso formulation this month and launch slim cans for Zola products in early 2027; it sees new distribution opportunities in 2027, including in Texas.
